Calamos Advisors LLC Sells 68,337 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Calamos Advisors LLC reduced its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 63.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,642 shares of the company's stock after selling 68,337 shares during the quarter. Calamos Advisors LLC's holdings in Cellebrite DI were worth $751,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Gen Wealth Partners Inc bought a new stake in shares of Cellebrite DI in the fourth quarter worth about $85,000. NewEdge Advisors LLC grew its stake in shares of Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after purchasing an additional 3,352 shares during the last quarter. Polen Capital Management LLC bought a new stake in shares of Cellebrite DI in the fourth quarter worth about $222,000. Victory Capital Management Inc. bought a new stake in shares of Cellebrite DI in the fourth quarter worth about $234,000. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in shares of Cellebrite DI in the first quarter worth about $269,000. 45.88% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on CLBT shares. JPMorgan Chase & Co. cut their target price on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Needham & Company LLC restated a "buy" rating and issued a $24.00 price objective on shares of Cellebrite DI in a report on Friday, June 6th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $22.43.

Cellebrite DI Stock Down 3.9%

Shares of CLBT stock traded down $0.60 during trading hours on Thursday, hitting $14.75. 1,587,274 shares of the company's stock traded hands, compared to its average volume of 1,577,363. The stock's fifty day simple moving average is $16.93 and its two-hundred day simple moving average is $19.36. Cellebrite DI Ltd. has a 12-month low of $11.49 and a 12-month high of $26.30. The stock has a market cap of $3.53 billion, a price-to-earnings ratio of -15.36, a PEG ratio of 3.07 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.01. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. The firm had revenue of $107.55 million during the quarter, compared to analyst estimates of $109.36 million. During the same period last year, the business earned $0.08 earnings per share. The business's revenue was up 20.0% on a year-over-year basis. On average, equities analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.